Research
Hormonal
Elafibranor (PPAR alpha/delta agonist) and Obeticholic Acid (FXR ligand) show promise in resolving NASH and improving fibrosis in clinical trials.
Elafibranor and Obeticholic Acid are emerging pharmacological treatments showing improvement in NASH and fibrosis in trials. They are not yet universally approved for NASH but are in Phase 3 testing.
ModerateSupportsMEDIUM confidence
The PPARα/δ ligand elafibranor was evaluated in the GOLDEN trial and appeared to resolve NASH in the subgroup with more severe disease at baseline who also received the highest dose [41]. ... obeticholic acid... resulting in improvements in the composite NAFLD activity score and fibrosis [42].
Why this rating
Based on Phase 2 trial results (GOLDEN, FLINT) mentioned in a review; Phase 3 trials are ongoing.
Source
Non-alcoholic fatty liver disease
Brent A. Neuschwander‐Tetri · BMC Medicine · 2017
DOI 10.1186/s12916-017-0806-8
narrative_reviewCited 462×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Lifestyle modification focusing on weight loss and exercise is the primary effective therapy for reversing features of non-alcoholic steatohepatitis (NASH) and fibrosis.Good
- Pioglitazone and Vitamin E are beneficial pharmacological interventions for non-diabetic NASH patients, and Pioglitazone improves fibrosis in diabetic patients.Good
- Liraglutide (GLP-1 analogue) barely met the primary endpoint for NASH resolution in a small trial, while Sitagliptin showed no effect on liver histology.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →